Editas Medicine, Inc. (EDIT)

Editas Medicine, Inc. is a biotechnology company that was founded in 2013 with a focus on developing transformative gene-editing therapies using CRISPR technology. The company's mission is to harness the potential of CRISPR technology to treat a range of serious diseases by directly editing genes. Editas is headquartered in Cambridge, Massachusetts, which is a hub for biotech innovation. As of 2023, the CEO is Gilmore O’Neill, who leads the company in its strategic initiatives and development programs. Editas continues to invest in research and development to advance its pipeline of potential therapies, striving to bring innovative solutions to patients who have limited or no treatment options. The company reportedly continues to explore partnerships and collaborations to further its technology and therapeutic reach.